Caricamento...
Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
Brodalumab, a monoclonal antibody that targets the interleukin-17 receptor, is a new treatment option for moderate-to-severe plaque psoriasis with a unique mechanism of action. The current recommended dosing regimen is a 210-mg subcutaneous injection at weeks 0, 1, and 2, and every 2 weeks thereafte...
Salvato in:
| Pubblicato in: | SAGE Open Med Case Rep |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7011332/ https://ncbi.nlm.nih.gov/pubmed/32095245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050313X20905672 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|